PTC Therapeutics PTCT Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Operating margin | 54.2%+91.7pp | -37.5%+10.0pp | -47.5%+16.5pp | -64%+5.5pp | |
| EBITDA margin | 56.5%+84.6pp | -28.1%-5.9pp | -22.3%+23.3pp | -45.6%+12.0pp | |
| Efficiency | |||||
| Asset turnover | 0.8×+0.3× | 0.4×-0.1× | 0.5×+0.1× | 0.4×+0.1× | |
| Liquidity | |||||
| Current ratio | 2.3×0.0× | 2.4×+0.3× | 2×+0.3× | 1.7×-0.2× | |
| Quick ratio | 2.3×0.0× | 2.3×+0.3× | 2×+0.3× | 1.7×-0.2× | |
| Cash ratio | 1×-0.3× | 1.3×+0.4× | 1×+0.3× | 0.7×+0.3× | |
| Leverage | |||||
| Debt-to-assets | 0.1×-0.1× | 0.2×0.0× | 0.2×-0.2× | 0.4×+0.1× | |
| Net debt / EBITDA | -0.6×— | —— | —— | —— | |
| Per Share | |||||
| Book value per share | -$2.32+83.7% | -$14.29-30.6% | -$10.94-126% | -$4.84-23,820% | |
| Valuation | |||||
| Market capitalization | $6.1B+75.2% | $3.48B+67.3% | $2.08B-25.3% | $2.79B-1.1% | |
| Enterprise value | $5.51B+78.2% | $3.09B+62.4% | $1.91B-40.7% | $3.21B+1.6% | |
| Price / sales | 3.5×-0.8× | 4.3×+2.1× | 2.2×-1.8× | 4×-1.2× | |
| EV / EBITDA | 5.6×— | —— | —— | —— | |
| EV / sales | 3.2×-0.6× | 3.8×+1.8× | 2×-2.6× | 4.6×-1.3× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are PTC Therapeutics's profit margins?
- PTC Therapeutics (PTCT) runs a 96.0% gross margin and a 1.6% operating margin, with a 42.3% net margin.
- Where do PTC Therapeutics's ratios come from?
- Every ratio is computed from PTC Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
